DSpace Fukushima Medical University

福島県立医科大学学術成果リポジトリ = Fukushima Medical University Repository >
福島医学会 = The Fukushima Society of Medical Science >
Fukushima Journal of Medical Science >
Vol.61 (2015) >

Please use this identifier to cite or link to this item: http://ir.fmu.ac.jp/dspace/handle/123456789/458

Files in This Item:

File Description SizeFormat
FksmJMedSci_61_p23.pdf705.2 kBAdobe PDFDownload
Title: Validation of therapeutic response assessment by bone scintigraphy in patients with bone-only metastatic breast cancers during zoledronic acid treatment: comparison with computed tomography assessment
Authors: Ishii, Shirou
Kikuchi, Ken
Miyajima, Masayuki
Sakuma, Kotaro
Shishido, Fumio
Affiliation: 放射線医学講座
Source title: Fukushima Journal of Medical Science
Volume: 61
Issue: 1
Start page: 23
End page: 31
Issue Date: 2015
Abstract: Purpose: To validate the use of bone scintigraphy (BS) versus computed tomography (CT) for therapeutic monitoring in patients during treatment with zoledronic acid. Materials and Methods: Eleven patients with bone-only metastatic disease and being treated with zoledronic acid were included. The effects of therapies including chemotherapy and hormone therapy were evaluated in 25 separate examinations in total as follows: complete response (CR), when no bone metastasis was visible; partial response (PR), when a decrease in the lesion area was detected; stable disease (SD), when no or slight change was observed; and progressive disease (PD), when new or enlarged lesion areas were observed. Results: The accuracies of examination by Readers 1, 2, and 3 respectively were 76%, 80% and 76% for BS, 52%, 48%, and 40% for CT, and 64%, 52% and 60% for BS and CT combined with Readers 2 and 3 observing significant differences between CT and BS results. The rates of interobserver agreement between Readers 1 and 2, between Readers 1 and 3, and between Reader 2 and 3 respectively, were 84%, 80% and 88% (κ = 0.648, 0.561 and 0.766) for BS, 52%, 56%, and 60% (κ = 0.180, 0.278 and 0.282) for CT, and 52%, 60%, and 56% (κ = 0.215, 0.282 and 0.232) for CT and BS combined. Conclusion: BS is effective for assessing the response of bone metastasis to therapy in patients during zoledronic acid treatment.
Publisher: The Fukushima Society of Medical Science
Publisher (Alternative foam): 福島医学会
language: eng
URI: http://ir.fmu.ac.jp/dspace/handle/123456789/458
Full text URL: http://ir.fmu.ac.jp/dspace/bitstream/123456789/458/1/FksmJMedSci_61_p23.pdf
ISSN: 0016-2590
DOI: 10.5387/fms.2013-15
PubMed ID: 25946906
Related Page: http://doi.org/10.5387/fms.2013-15
Rights: © 2015 The Fukushima Society of Medical Science
Appears in Collections:Vol.61 (2015)

Files in This Item:

File Description SizeFormat
FksmJMedSci_61_p23.pdf705.2 kBAdobe PDFDownload

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.


DSpace Software Copyright © 2002-2007 MIT and Hewlett-Packard